Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pump it
Investors deck updated
Press Release: PharmaTher Announces Sale of Psilocybin Program
PharmaTher Announces Sale of Psilocybin Program
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. ("PharmaTher" or the "Company"), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement (the "Agreement") with Revive Therapeutics Ltd. ("Revive") (CSE: RVV, USA: RVVTF) to sell the full rights to PharmaTher's intellectual property (the "Acquired Assets") pertaining to psilocybin (the "Acquisition").
Pursuant to the Agreement, Revive will pay aggregate consideration of up to CAD $10 million (the "Purchase Price"). The Purchase Price will be satisfied as follows: (i) $3 million in cash will be paid on the closing date; (ii) $4 million will be satisfied through the issuance of securities in the capital of Revive and (iii) up to $3 million, in either cash or securities in the capital of Revive, in the event that Revive achieves certain milestones, which include Revive obtaining FDA orphan drug designation for psilocybin in the treatment of stroke, traumatic brain injury, or cancer, the commencement of a Phase 2 clinical trial and the regulatory filing for market authorization, such as U.S. Food and Drug Administration ("FDA") approval. In addition to the Purchase Price, Revive will also pay Newscope Capital Corporation a low single digit royalty on all future net sales of products derived from the Acquired Assets.
"We are very pleased with the sale of our psilocybin program as it pertains to the intellectual property and research for the use of psilocybin in the treatment of stroke, traumatic brain injury and cancer to Revive as it provides us with non-dilutive funding to advance the clinical development of ketamine in the treatment of Parkinson's disease, KETABET(TM) in the treatment of depression and the development of our proprietary microneedle delivery technologies to deliver psychedelic pharmaceuticals including ketamine, esketamine, psilocybin, MDMA, LSD and DMT for various mental health, neurological and pain disorders," said Fabio Chianelli, CEO of PharmaTher. "We are now in a strong position to unlock the value of our unique psychedelic-based product pipeline and microneedle delivery technologies, and to advance our lead program ketamine to treat Parkinson's disease towards FDA Phase 2 clinical trials."
"We are pleased with our purchase of PharmaTher's psilocybin portfolio as it complements Revive's current psilocybin-based programs in oral thin film delivery, a clinical study for a drug abuse disorder and the development of a biosynthetic version of psilocybin," said Michael Frank, CEO of Revive. "Revive is positioned to advance its unique prescription-based psilocybin program for future clinical development with the objective in commercializing its product offerings through the FDA approval pathway."
The Acquired Assets will include all of the following:
-- All intellectual and work property derived from pre-clinical research activities from the National Health Research Institutes ("NHRI") in traumatic brain injury and stroke, as it relates to psilocybin with the aim to obtain FDA Orphan Drug Designation. -- Key provisional patent applications with the U.S. Patent and Trademark Office, which include:(i) Psilocybin in the Treatment of Neurological Brain Injury - United States Provisional Application Serial No. 63/011,493 -- Relates to pharmaceutical compositions comprising psilocybin and their use for the treatment of neurological brain injuries and migraines.(ii) Use of Psilocybin in the Treatment of Cancer, United States Provisional Application Serial No. 63/113,913 -- Psilocybin's use of significant unmet medical needs for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.(iii) Psilocybin Pharmaceutical Combination Therapies, United States Provisional Application Serial No. 63/125,106 -- Novel combinations of certain FDA approved drugs with psilocybin as a potential therapeutic option to reduce the side effects and improve the effectiveness of psilocybin to treat neurological disorders.
The Company cautions that psilocybin is still under early-stage research and development and is not making any express or implied claims as to their success alone and in combination of FDA approved drugs or commercial viability.
About PharmaTher Inc.
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological and pain disorders.
Learn more at: PharmaTher.com and follow us on Twitter, LinkedIn and Facebook.
For more information, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Inc.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
0420 is so high right now
Email from dennis. Got this from reddit investor group https://www.reddit.com/r/DPLS/comments/ljuhi2/as_requested_email_screenshot_with_denis_oleary/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Yuuuuuuuugggggge
.10cents
Website updated, This logo added today.
Expecting contract news soon
$DPLS
— Sandesh Acharya (@achsandesh) February 12, 2021
Website updated, This logo added today.
Expecting contract news soonhttps://t.co/8WAqJZrqni$TSNP $MJNA $AITX $SNDL $HCMC pic.twitter.com/LXhqhqiW7q
$DPLS
— Sandesh Acharya (@achsandesh) February 12, 2021
Website updated, This logo added today.
Expecting contract news soonhttps://t.co/8WAqJZrqni$TSNP $MJNA $AITX $SNDL $HCMC pic.twitter.com/LXhqhqiW7q
Scooped 21k boom
Monies
Was able to add 1000 shares not bad. I am
Happy sitting at 50k shares ready for to just wait for that big leg up!
Today is primary completion date. I’m sure news will hit at noon!
Idk if anyone saw this on RioDad’s post on twitter.
https://twitter.com/hoard11/status/1355385875539120132?s=21 oral vaccine huh?
That $8.50 print
.@mindmedco CEO JR Rahn on the launch of the first psychedelic ETF: “What we’re seeing now is... a demand from both retail investors and institutional investors on how to best index this space and how to gain the most exposure to the most amount of clinical trials.” pic.twitter.com/8I2HX91COl
— Yahoo Finance (@YahooFinance) January 25, 2021
Out of all the companies listed on the ETF Mindmed got the interview? What does that tell you! They are leading this sector!!!
Damn and my deposit doesn’t clear yet til Wednesday
DPLS twitter is posting some news but is it more like a reminder of what’s coming?
Time to hit back ATH ladies and gents
#Today: #SALTTalks: Psychedelics with Sa'ad Shah, @NoeticFund, and @TheJRRahn, @MindMedCo.
Moderated by @SALTConference Chairman Anthony @Scaramucci.
Register at bit.ly/2MNeiGo
Can dpls reach a dollar?
Cannacord also bought shares at Mindmed 3x and guess where they are now. $3+ and at one point even ran to $5. The fact that Cannacord is dipping on RVV is a big freaking deal.
Opps wrong board
Added 5k now holding 15k so happy averaging around .40’s
So 30 days above $2 on jan 20? Sounds like a perfect timing
Mindmed is also the largest as mentioned!!!
As the Focus on Psychedelic Stocks Increases, So Do the Valuations
https://realmoney.thestreet.com/investing/cannabis/as-the-focus-on-psychedelic-stocks-increases-so-do-the-valuations-15535386
Also that ETF on Jan 15. So much things are coming and they are actually aligned well.
Right! It was just odd that they sent an email with News round up. News Roundup
What’s Next For Mindmed After They Close Their Upsized $92.1 Million Financing (JR Rahn Interview)
"We have a federally regulated approach. This is the main thing that CIBC was looking at; they wanted nothing to do with state-by-state legalization efforts, they wanted nothing to do with recreational market. Federal compliance is going to be super important."
See original video here
Is it time to rehabilitate psychedelics?
"JR Rahn is the founder of MindMed, a New York-based startup, which is developing psychedelic drugs to treat mental illness and addiction. 'Translating this science into scalable medicines,' he says."
See original article here
Why The Psychedelics Market Is NOT Cannabis 2.0
"Psychedelics, however, offer hundreds of various molecules that can be developed, tested, and deployed through the same process biotech companies and Big Pharma develop, test, and deploy their products into the marketplace. And it doesn’t take a rocket scientist to know that if you latch onto the right biotech or pharma play, that has the right product, you can easily see 10, 20, 30X returns. It happens all the time, and I foresee the psychedelics market playing out the same way."
See original article here
Mind Medicine: Why Kevin O'Leary Thinks This Psychedelics Company Is Just Getting Started
"Shark Tank star Kevin O'Leary has invested in hundreds of businesses over the years, some on-screen and some off. But few have attracted as much attention as his investment in psychedelic drug company Mind Medicine (OTC:MMED.F), also known as MindMed."
See original article here
Everyone said 'no' to MindMed, now it's worth $2 billion with 'unicorn' status
"MindMed (MMED.NE) has surpassed the $2 billion market cap on Monday when shares surged 35% by midday. Year-to-date, the company’s stock more than 10 times, from 53 cents in March to $5.60 by the end of the trading day.
Institutional investors are starting to come into the psychedelic drug space because the danger of mental health issues is becoming a serious problem for society."
See original article here
The Case for Macrodosing
"The US military is funding research into psychedelic compounds that don’t make you trip and Canadian pharmaceutical company MindMed is developing a psychedelic off-switch, as examples."
See original article here
I really don’t know just wishing. And besides they sent out an email summary of news over the weekend.
I think news is dropping today after hours....